Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 2,162 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Ancillary Study Clear all
Active, not recruiting Phase 3 Interventional

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT01863550
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Bortezomib, Carfilzomib, Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide, Quality-of-Life Assessment
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
1,087 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2034
U.S. locations
909
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Hot Springs, Arkansas + 551 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 23, 2026, 5:40 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer

NCT03040726
View directory record Official record
Conditions
Malignant Neoplasm, Nausea, Vomiting
Interventions
Netupitant, Palonosetron, Palonosetron Hydrochloride, Placebo, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 23, 2026, 5:40 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

NCT04576117
View directory record Official record
Conditions
Recurrent Low Grade Astrocytoma, Recurrent WHO Grade 2 Glioma, Refractory Low Grade Astrocytoma, Refractory Low Grade Glioma, Refractory WHO Grade 1 Glioma
Interventions
Biospecimen Collection, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Selumetinib Sulfate, Vinblastine Sulfate
Procedure · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 25 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
91
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 77 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 23, 2026, 5:40 PM EDT
Completed Not applicable Interventional

Exercise in Improving Health and Quality of Life in Breast Cancer Survivors

NCT03679559
View directory record Official record
Conditions
Invasive Breast Carcinoma
Interventions
Best Practice, Exercise Intervention (home walking program and resistance training), Exercise Intervention (home-based Zumba program and resistance training), Exercise Intervention (HIIT program and resistance training), Informational Intervention, Laboratory Biomarker Analysis, Monitoring Device, Quality-of-Life Assessment, Questionnaire Administration
Other · Behavioral · Device
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Not listed
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 23, 2026, 5:40 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma

NCT02500576
View directory record Official record
Conditions
Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Aldesleukin, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Pembrolizumab, Quality-of-Life Assessment, Therapeutic Tumor Infiltrating Lymphocytes
Biological · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 23, 2026, 5:40 PM EDT
Completed Phase 3 Interventional

Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic

NCT00003440
View directory record Official record
Conditions
HER2-negative Breast Cancer, HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
paclitaxel, trastuzumab, quality-of-life assessment, laboratory biomarker analysis
Drug · Biological · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 23, 2026, 5:40 PM EDT
Recruiting Not applicable Interventional

Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia

NCT06710418
View directory record Official record
Conditions
Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Myeloid Neoplasm
Interventions
Activity Tracking, Biospecimen Collection, Cognitive Assessment, Electronic Health Record Review, Packed Red Blood Cell Transfusion, Quality-of-Life Assessment
Other · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 23, 2026, 5:40 PM EDT
Completed Phase 3 Interventional Results available

Oxybutynin Chloride in Managing Hot Flashes

NCT02961790
View directory record Official record
Conditions
Breast Carcinoma, Ductal Breast Carcinoma In Situ, Hot Flashes, Lobular Breast Carcinoma In Situ, No Evidence of Disease
Interventions
Oxybutynin Chloride, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
13
States / cities
Peoria, Illinois • Urbana, Illinois • Cedar Rapids, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 23, 2026, 5:40 PM EDT
Recruiting Not applicable Interventional

Sauna for Long Covid

NCT05931497
View directory record Official record
Conditions
Long COVID
Interventions
whole body hyperthermia
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 23, 2026, 5:40 PM EDT
Recruiting Phase 2 Interventional

Axatilimab for Sclerotic Chronic Graft-versus-Host Disease

NCT07011810
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Axatilimab, Biospecimen Collection, Questionnaire Administration, Skin Biopsy, Skin Measurement
Biological · Procedure · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Tampa, Florida • Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 5:40 PM EDT
Terminated Not applicable Interventional

Impact of Phone Call About Financial Reimbursement Program on Access to Cancer Clinical Trials

NCT03943082
View directory record Official record
Conditions
Malignant Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Cancer Educational Materials, Follow-Up Care, Questionnaire
Behavioral · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
7 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 23, 2026, 5:40 PM EDT
Completed No phase listed Observational

Survey of Post-Acute Inpatient Rehabilitation Safety Concerns in Participants With Cancer

NCT03656224
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Survey Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Oct 23, 2026, 5:40 PM EDT
Not yet recruiting Not applicable Interventional

A Wearable Biosensor Patch for Non-Invasive Monitoring for Patients Undergoing Abdominal or Chest Surgery

NCT07612085
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Electronic Health Record Review, Interview, Survey Administration, Wearable Biosensor Patch
Procedure · Other · Device
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 5:40 PM EDT
Recruiting Phase 3 Interventional

Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma

NCT07452458
View directory record Official record
Conditions
Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Questionnaire Administration, Radiation Therapy, Temozolomide, Temporally-modulated Pulsed Radiation Therapy
Procedure · Other · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
54
States / cities
Irvine, California • Los Angeles, California • Orange, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 23, 2026, 5:40 PM EDT
Recruiting Phase 2 Interventional

Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

NCT06930352
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cytarabine, Echocardiography Test, Hydroxyurea, Leukapheresis, Multigated Acquisition Scan, Questionnaire Administration, Ziftomenib
Procedure · Drug · Other
Lead sponsor
Uma Borate
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 23, 2026, 5:40 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

NCT02567435
View directory record Official record
Conditions
Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma, Rhabdomyosarcoma, Sclerosing Rhabdomyosarcoma, Spindle Cell Rhabdomyosarcoma
Interventions
Cyclophosphamide, Dactinomycin, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Questionnaire Administration, Radiation Therapy, Temsirolimus, Vincristine Sulfate, Vinorelbine
Drug · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 40 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
355
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 210 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 5:40 PM EDT
Completed Not applicable Interventional

Cardiac Rehabilitation Program in Improving Cardiorespiratory Fitness in Stage 0-III Breast Cancer Survivors

NCT03039140
View directory record Official record
Conditions
Cancer Survivor, Stage 0 Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Educational Intervention, Exercise Intervention, Quality-of-Life Assessment, Questionnaire Administration
Other · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
30 Years to 75 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 23, 2026, 5:40 PM EDT
Recruiting Phase 2 Interventional

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

NCT06997068
View directory record Official record
Conditions
Metastatic Oral Cavity Carcinoma, Recurrent Oral Cavity Carcinoma, Stage IVC Lip and Oral Cavity Cancer AJCC v8, Head and Neck Cancer, Hypopharynx Cancer, Oropharynx Cancer, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Hypopharyngeal Carcinoma, Metastatic Laryngeal Carcinoma, Metastatic Malignant Head and Neck Neoplasm, Metastatic Oropharyngeal Carcinoma, Recurrent Hypopharyngeal Carcinoma, Recurrent Laryngeal Carcinoma, Recurrent Malignant Head and Neck Neoplasm, Recurrent Oropharyngeal Carcinoma, Stage IVC Hypopharyngeal Carcinoma AJCC v8, Stage IVC Laryngeal Cancer AJCC v8, Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Celecoxib, Erlotinib Hydrochloride, Imaging Procedure, Interview, Methotrexate, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 5:40 PM EDT
Completed Not applicable Interventional Results available

Communicating Health Information and Improving Coordination With Primary Care

NCT03104543
View directory record Official record
Conditions
Hypertension, Dyslipidemias, Diabetes, Childhood Cancer
Interventions
Education, Test results only
Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 23, 2026, 5:40 PM EDT
Completed Phase 3 Interventional Results available

Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer

NCT01414608
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7
Interventions
Brachytherapy, Carboplatin, Cisplatin, External Beam Radiation Therapy, Paclitaxel, Quality-of-Life Assessment
Radiation · Drug · Other
Lead sponsor
GOG Foundation
Network
Eligibility
18 Years and older · Female only
Enrollment
926 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
315
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 220 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 23, 2026, 5:40 PM EDT
Terminated No phase listed Observational

Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer

NCT05575440
View directory record Official record
Conditions
Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma, Thyroid Gland Papillary Carcinoma
Interventions
Computed Tomography, Fluorine F 18 Tetrafluoroborate, Positron Emission Tomography, Survey Administration
Procedure · Radiation · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 5:40 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

NCT06195306
View directory record Official record
Conditions
Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions
Biospecimen Collection, Mammography, Omega-3-Acid Ethyl Esters, Questionnaire Administration, Random Periareolar Fine-Needle Aspiration, Tamoxifen
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
45 Years to 74 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
3
States / cities
Kansas City, Kansas • Ann Arbor, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 23, 2026, 5:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Filter Ventilation and Ventilation Information on Product Use Behaviors in Cigarette Smokers

NCT04744285
View directory record Official record
Conditions
Cigarette Smoking-Related Carcinoma
Interventions
Cigarette packaging, Data capture, Questionnaire administration
Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
21 Years to 69 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 23, 2026, 5:40 PM EDT
Recruiting Phase 1 Interventional

Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

NCT07025538
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm
Interventions
Best Practice, Biomarker Analysis, Biospecimen Collection, Questionnaire Administration, Ruxolitinib
Other · Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 23, 2026, 5:40 PM EDT